Aktienanalyse zu TG Therapeutics Inc (TGTX)TGTXTG Therapeutics Inc

TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

TG Therapeutics Inc (TGTX) is a good buy right now, as it is currently priced at $55.37, with a strong year-to-date change of +89.11%. The company's gross margin stands at 82.86%, indicating solid profitability, and analysts project a price target of $78, suggesting significant upside potential. However, the main risk is the recent earnings report, which showed an EPS of only $0.05, significantly below the estimate of $0.41, reflecting potential volatility in investor sentiment.

5 analysts cover TGTX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 43.50.